Jill Kozeny, 202-224-1308
Sen. Grassley asks questions about controversy over delayed release of drug study involving Vytorin
M E M O R A N D U M
TO: Reporters and Editors
FR: Jill Kozeny, 202/224-1308 for U.S. Senator Chuck Grassley
RE: Controversy over delayed release of drug trial on Vytorin
DA: Thursday, January 24, 2008
Senator Chuck Grassley, Ranking Member of the Committee on Finance, is asking drug
makers Schering-Plough and Merck to explain when the companies first unblinded ENHANCE
trial results and to account for sales and payments made for the cholesterol drug Vytorin to
Medicaid. Senator Grassley has also written to the Securities and Exchange Commission, the
American Heart Association and the American College of Cardiology regarding this matter.
Copies of all four letters are posted with this statement at http://finance.senate.gov.
Schering-Plough and Merck recently released the results of the ENHANCE trial which
studied whether Vytorin performed as well as a generic statin to lower cholesterol levels.
Vytorin is a combination pill of ezetimibe and a generic statin. The ENHANCE trial results
found that Vytorin performed just as well as a much cheaper statin. The professional
associations issued statements at the time the ENHANCE study was released, so Sen. Grassley is
asking for more information about contributions to this statement. For the past three years,
Senator Grassley has conducted oversight of various federal agencies and companies to ensure
that peer reviewed science forms the basis for decisions in healthcare and healthcare payments.
Senator Grassley’s comment:
“In Iowa City, generic simvastatin costs $54.54 for a month’s supply while Vytorin costs
$112.46. It’s fair to assume the public would have benefitted from knowing that a less expensive
drug works just as well. Instead, people in Iowa and elsewhere paid more for nearly two years
while industry leaders sat on a scientific study that would have revealed this information.”
Next Article Previous Article
- Wyden: Supercharging Budget Reconciliation Puts Americans’ Health Coverage and Economy At Risk
- Wyden Introduces Legislation to Reform Opportunity Zone Program
- Wyden, Neal Investigate Abuse of Opportunity Zone Program
- Wyden, Neal, Booker, Lewis Request GAO Study on Opportunity Zone Program
- Wyden Statement on Legislation to Rein in Donald Trump’s Tariff Authority